Monitor for subsequent pricing detail disclosures or government program expansions that could affect Attruby's revenue trajectory. Key catalysts to watch are the upcoming PDUFA dates for BBP-418 (Nov 2026) and encaleret (May 2027).
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 31 $76.59entry
- T+1 · 3mo ago −0.03%α +0.66% · $76.57
- T+5 · 2mo ago −2.39%α −2.25% · $74.76
- T+20 · 7w ago −13.87%α −13.68% · $65.97
- T+54 · todayOpen
- T+60 · in 7d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BridgeBio announced a voluntary agreement with the U.S. government to lower drug costs and expand Medicaid access to its marketed medicine Attruby, with no future pricing mandates expected. The specific terms are confidential, but the deal excludes medicines approved exclusively for orphan indications and has no impact on the company's existing copay assistance program.
Key Facts
- Voluntary agreement with U.S. government to lower drug costs and expand Medicaid access to Attruby via the GENEROUS Model
- BridgeBio expects no future pricing mandates under this agreement
- Pricing commitments exclude medicines approved exclusively for orphan indications
- Attruby will continue to be offered via Medicare Part D without future pricing mandates
- The ForgingBridges copay assistance program is unaffected
- Specific terms of the agreement remain confidential
- CEO Neil Kumar joined President Trump at the White House to discuss the agreement
- BridgeBio has three additional medicines under FDA review: BBP-418 (PDUFA Nov 27, 2026), encaleret (PDUFA May 7, 2027), and infigratinib for achondroplasia
Financial Impact
No specific dollar amounts disclosed, agreement terms are confidential. Impact on pricing and revenue for Attruby and future medicines is unquantifiable from this filing.
Risk Factors
- Implementation of the agreement may differ from current expectations
- Future changes in federal laws or pricing programs could override the agreement's protections
- Confidential terms may have undisclosed revenue or pricing constraints
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-035055 |
| Document: ef20081330_ex99-1.htm | 0001140361-26-035055 |
| Document: 0001140361-26-035055-index-headers.html | 0001140361-26-035055 |
| Document: 0001140361-26-035055-index.html | 0001140361-26-035055 |
| Document: 0001140361-26-035055.txt | 0001140361-26-035055 |
Track record
38 reports on BBIO
10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers